Journal
CANCER AND METASTASIS REVIEWS
Volume 24, Issue 4, Pages 585-598Publisher
SPRINGER
DOI: 10.1007/s10555-005-6197-x
Keywords
monoclonal antibody; oncology; antibody manufacture; antibody-dependent cell cytotoxicity (ADCC); complement-mediated cytolysis (CMC); clinical trial
Categories
Ask authors/readers for more resources
The past five years have witnessed the emergence of monoclonal antibodies as important therapeutics for cancer treatment. Lower toxicity for antibodies versus small molecules, the potential for increased efficacy by conjugation to radioisotopes and cellular toxins, or the ability to exploit immune cell functions have led to clinical performances on par or superior to conventional drug therapies. This review outlines the various immunoglobulin design strategies currently available, techniques used to reduce Ig antigenicity and toxicity, and points to consider during the manufacture of antibodies for use in clinical oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available